Key result
Elevated apoB/A1 ratio linked to ~57% greater heart failure severity in ischemic or hypertensive disease.
Why the study?
It was unknown whether the circulating apoB/A1 ratio could serve as a metabolic risk factor for chronic heart failure severity across multiple etiologies.
Is an elevated circulating apoB/A1 ratio associated with increased heart failure severity in patients with chronic HF?
Population
1285 consecutive chronic HF patients and 1392 healthy controls
Comparison
Chronic HF severity groups (HFpEF, HFmrEF, HFrEF) vs healthy controls
Design
Cross-sectional study
Authors
Loading...
ApoB/A1 ratio should not guide HF management yet; leaves open its role as a severity marker in ischemic or hypertensive subtypes.
Cross-Sectional (n=2,677)
No
Is an elevated circulating apoB/A1 ratio associated with increased heart failure severity in patients with chronic HF?
Odds Ratio: 1.571 (95% CI 1.362–1.812)
p-value: p=<0.001
An elevated circulating apoB/A1 ratio is significantly associated with worsened left ventricular dysfunction and heart failure severity, particularly in patients with ischemic or hypertensive heart disease.
Zhou et al. (2026) conducted a cross-sectional in Chronic heart failure (n=2,677). Apolipoprotein B/A1 ratio vs. Lower apoB/A1 ratio was evaluated on Heart failure classification severity (HFpEF, HFmrEF, HFrEF) (OR 1.571, 95% CI 1.362-1.812, p=<0.001). An elevated circulating apolipoprotein B/A1 ratio was significantly associated with more severe heart failure classification (OR 1.571), particularly in patients with ischemic or hypertensive heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: